Search

Displaying results 2641 - 2650 of 10000 in total
  1. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. … It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.

  2. Drug

    Cobomarsen

    go.drugbank.com/drugs/DB14931
    Investigational

    Cobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL).

  3. Drug

    WP-1122

    go.drugbank.com/drugs/DB17192
    Investigational

    WP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]

    Synonyms: an acetic acid diester of 2-deoxy-D-glucose, 3,6-di-O-acetyl-2-deoxy-D-glucopyranose
  4. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. … As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension

    Mixtures: DUACT 8 MG/60 MG KAPSÜL, 30 ADET, Semprex-D
  5. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

  6. Drug

    Mestranol

    go.drugbank.com/drugs/DB01357
    ApprovedWithdrawn

    It is used as the estrogen component of many combination ORAL contraceptives.

    Mixtures: Norinyl 1/50 28 Tab, Norinyl 1/50 21 TabCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  7. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative … However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent

  8. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor.

  9. Drug

    Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19344
    ApprovedInvestigational

    pneumoniae_ serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197). … Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains de-O-acetylated saccharides of the capsular antigens of _Streptococcus

  10. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)